Welcome to our dedicated page for Elicio Therapeutics news (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company focused on transforming cancer treatment through cutting-edge immunotherapies. By leveraging its proprietary Amphiphile (AMP) platform, Elicio is developing vaccines and immunotherapies targeting aggressive cancers such as pancreatic, colorectal, and head and neck cancers.
The AMP platform uniquely targets and delivers immunogens directly to the lymphatic system, amplifying the body's immune response to fight cancer and prevent its recurrence. This innovative approach aims to unlock the full potential of the human immune system, resulting in enhanced anti-tumor functionality and long-term protective memory.
Recent achievements include:
- The commencement of initial patient studies for its lead amphiphile vaccines targeting various cancers in early 2020.
- Ongoing Phase 1 and Phase 2 trials for ELI-002, a novel cancer vaccine targeting mutant KRAS-driven tumors.
- The publication of promising preclinical and clinical data which demonstrate the AMP platform's potential in enhancing T cell responses and eradicating solid tumors.
Financial updates reveal continued investment in clinical trials and research, with expenses reflecting the company's robust R&D initiatives. Partnerships with renowned institutions like the University of Texas MD Anderson Cancer Center further bolster Elicio's research capabilities.
Looking forward, Elicio plans to advance its development pipeline, including the ELI-002 7P Phase 2 trial as a monotherapy for patients with pancreatic ductal adenocarcinoma (PDAC). The company remains committed to pioneering new cancer treatments and improving patient outcomes.
Rhea-AI Summary
Elicio Therapeutics, a biotechnology company, has entered into a subscription agreement to sell pre-funded warrants to purchase shares of its common stock in a private placement to GKCC, The gross proceeds are expected to be $6.0 million, with the net proceeds intended for the company's development pipeline and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28%
Tags
-
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced three upcoming poster presentations at the AACR Annual Meeting showcasing their innovative cancer vaccine candidates. The presentations will focus on the immunogenicity and efficacy of their AMP technology in targeting solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
-
News
Rhea-AI Summary
Elicio Therapeutics, Inc. (ELTX) is set to present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The CEO, Robert Connelly, will be presenting the clinical-stage biotechnology company's pipeline of novel immunotherapies for cancer treatment. The presentation will be available via live webcast and on-demand for 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
Rhea-AI Summary
Elicio Therapeutics, Inc. announced promising preclinical data in Cancer Immunology Research, showing that their AMP immunotherapy platform enhanced TCR-T cell therapy, leading to complete eradication of solid tumors refractory to TCR-T cell monotherapy. The AMP treatment also promoted immune activation in lymph nodes, invigorating anti-tumor T cell immunity. The study demonstrated long-term protection against tumor recurrence and antigen spreading to additional tumor-associated antigens. Preclinical efficacy in solid tumors, including those with KRAS mutations, provides a strong rationale for the clinical advancement of a combination AMP immunotherapy strategy with TCR-T cell therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
-
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced the Phase 1/2 (AMPLIFY-7P) study design for ELI-002 7P, a therapeutic cancer vaccine for KRAS-mutated pancreatic ductal adenocarcinoma. The study aims to evaluate its antitumor activity and clinical benefit. ELI-002 7P is designed to stimulate an immune response against seven KRAS mutations, with preliminary data showing tumor biomarker reduction and reduced risk of relapse and death. The study includes Phase 1A safety evaluation, Phase 1B dose expansion, and a Phase 2 randomized study assessing disease-free survival. Key endpoints include biomarker reduction, median overall survival, safety, and iRECIST response rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
-
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced that its CEO and EVP will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference. The chat will be accessible via RSVP to a B. Riley Securities sales representative and a replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
News
Rhea-AI Summary
Elicio Therapeutics, Inc. (ELTX) announces the dosing of the first patient in the Phase 2 study of ELI-002 7P, a therapeutic cancer vaccine targeting seven common mutations in KRAS, at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research. The vaccine aims to treat pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. Elicio's proprietary AMP technology targets more mutations compared to other KRAS-targeted therapies, potentially benefiting a larger patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
-
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced promising results from the Phase 1 study of ELI-002 in Nature Medicine, demonstrating robust, polyfunctional, and durable KRAS-specific CD4+ and CD8+ T cell responses in cancer patients. The study showed an 84% reduction in tumor biomarkers, correlating with a median relapse-free survival of 16.3 months. A Phase 2 trial for ELI-002 in pancreatic ductal adenocarcinoma is planned to start in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.31%
Tags
-
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) has entered into a subscription agreement to sell 1,213,000 shares of its common stock at a purchase price of $5.81 per share in a private placement to GKCC, LLC, controlled by a member of Elicio’s Board of Directors. The gross proceeds of the private placement are expected to be approximately $7.0 million, with the net proceeds intended for the advancement of its development pipeline, as well as for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.21%
Tags
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) will present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on December 6, 2023. The company is a clinical-stage biotechnology firm focusing on developing immunotherapies for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.04%
Tags
FAQ
What is the current stock price of Elicio Therapeutics (ELTX)?
The current stock price of Elicio Therapeutics (ELTX) is $5.62 as of January 3, 2025.
What is the market cap of Elicio Therapeutics (ELTX)?
The market cap of Elicio Therapeutics (ELTX) is approximately 58.6M.
What is Elicio Therapeutics' core business?
Elicio Therapeutics focuses on developing innovative cancer immunotherapies using its proprietary Amphiphile (AMP) platform.
What is the AMP platform?
The AMP platform delivers immunogens directly to the lymph nodes to amplify the immune response against cancer.
What are Elicio's lead products?
Elicio's lead product is ELI-002, a cancer vaccine targeting mutant KRAS-driven tumors, currently in Phase 1 and Phase 2 trials.
What types of cancer does Elicio's AMP platform target?
Elicio's AMP platform targets aggressive cancers like pancreatic, colorectal, and head and neck cancers.
What recent progress has Elicio made in its research and development?
Elicio has started initial patient studies for its lead vaccines, published promising preclinical data, and is conducting Phase 1 and Phase 2 trials for ELI-002.
Who are some of Elicio's research partners?
Elicio has partnered with renowned institutions like the University of Texas MD Anderson Cancer Center.
What is the financial status of Elicio Therapeutics?
Elicio continues to invest in R&D with increased expenses due to ongoing trials and research, reflecting its commitment to developing innovative cancer treatments.
What is the significance of ELI-002 7P formulation?
ELI-002 7P targets seven common KRAS mutations, increasing potential patient coverage and aiming to reduce cancer recurrence.
What are the future plans for Elicio Therapeutics?
Elicio plans to continue advancing its development pipeline, including Phase 2 trials for ELI-002 7P, and exploring new immunotherapy candidates.
How does Elicio aim to enhance the immune system's cancer-fighting capabilities?
Elicio’s AMP platform directs therapeutic payloads to lymph nodes, optimizing immune responses to recognize and eliminate tumor cells.
Elicio Therapeutics, Inc.
Nasdaq:ELTX
ELTX Rankings
ELTX Stock Data
58.60M
7.93M
26.08%
5.82%
0.4%
Biotechnology
Pharmaceutical Preparations
United States of America
BOSTON